JP2024515650A5 - - Google Patents

Info

Publication number
JP2024515650A5
JP2024515650A5 JP2023563210A JP2023563210A JP2024515650A5 JP 2024515650 A5 JP2024515650 A5 JP 2024515650A5 JP 2023563210 A JP2023563210 A JP 2023563210A JP 2023563210 A JP2023563210 A JP 2023563210A JP 2024515650 A5 JP2024515650 A5 JP 2024515650A5
Authority
JP
Japan
Application number
JP2023563210A
Other languages
Japanese (ja)
Other versions
JPWO2022221697A5 (https=
JP2024515650A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025076 external-priority patent/WO2022221697A1/en
Publication of JP2024515650A publication Critical patent/JP2024515650A/ja
Publication of JP2024515650A5 publication Critical patent/JP2024515650A5/ja
Publication of JPWO2022221697A5 publication Critical patent/JPWO2022221697A5/ja
Pending legal-status Critical Current

Links

JP2023563210A 2021-04-17 2022-04-15 脂質ナノ粒子組成物 Pending JP2024515650A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163176227P 2021-04-17 2021-04-17
US63/176,227 2021-04-17
US202163254948P 2021-10-12 2021-10-12
US63/254,948 2021-10-12
US202163274153P 2021-11-01 2021-11-01
US63/274,153 2021-11-01
US202263316568P 2022-03-04 2022-03-04
US63/316,568 2022-03-04
PCT/US2022/025076 WO2022221697A1 (en) 2021-04-17 2022-04-15 Lipid nanoparticle compositions

Publications (3)

Publication Number Publication Date
JP2024515650A JP2024515650A (ja) 2024-04-10
JP2024515650A5 true JP2024515650A5 (https=) 2025-04-21
JPWO2022221697A5 JPWO2022221697A5 (https=) 2025-04-21

Family

ID=81580499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563210A Pending JP2024515650A (ja) 2021-04-17 2022-04-15 脂質ナノ粒子組成物

Country Status (14)

Country Link
US (1) US20250090471A1 (https=)
EP (1) EP4322920A1 (https=)
JP (1) JP2024515650A (https=)
KR (1) KR20240017792A (https=)
AU (1) AU2022257050A1 (https=)
BR (1) BR112023021477A2 (https=)
CA (1) CA3216877A1 (https=)
CL (1) CL2023003077A1 (https=)
CO (1) CO2023015485A2 (https=)
CR (1) CR20230536A (https=)
IL (1) IL307738A (https=)
MX (1) MX2023012235A (https=)
TW (1) TW202308597A (https=)
WO (1) WO2022221697A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3234127A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2024138189A2 (en) 2022-12-22 2024-06-27 Intellia Therapeutics, Inc. Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
WO2024199282A1 (zh) * 2023-03-28 2024-10-03 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025049481A1 (en) * 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Methods of editing an hla-a gene in vitro
WO2025049432A1 (en) * 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01
WO2025064396A1 (en) 2023-09-18 2025-03-27 Intellia Therapeutics, Inc. Nuclease resistant double stranded dna product for non-viral delivery to a cell and methods of production thereof
WO2025064401A1 (en) 2023-09-18 2025-03-27 Intellia Therapeutics, Inc. Nuclease resistant single stranded dna product for non-viral delivery to a cell and methods of production thereof
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025137301A1 (en) * 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Methods for rapid engineering of cells
WO2025240946A1 (en) 2024-05-17 2025-11-20 Intellia Therapeutics, Inc. Lipid nanoparticles and lipid nanoparticle compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083272A1 (en) 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011091324A2 (en) 2010-01-22 2011-07-28 The Scripps Research Institute Methods of generating zinc finger nucleases having altered activity
CN103668470B (zh) 2012-09-12 2015-07-29 上海斯丹赛生物技术有限公司 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2019147805A2 (en) 2018-01-26 2019-08-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatory t cells targeted with chimeric antigen receptors
AU2020248337A1 (en) * 2019-03-28 2021-11-04 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
US12569438B2 (en) * 2019-07-29 2026-03-10 Georgia Tech Research Corporation Nanomaterials containing constrained lipids and uses thereof

Similar Documents

Publication Publication Date Title
JP2024515650A5 (https=)
CL2025003878A1 (es) Sistemas de generación de energía a partir de fuentes geotérmicas y métodos de operación y construcción de los mismos.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307046253S (https=)
CN307048966S (https=)
BY13144U (https=)
BY13143U (https=)
BY13142U (https=)
BY13141U (https=)
CN307046901S (https=)
CN307046678S (https=)
BY13140U (https=)
CN307046593S (https=)
CN307047695S (https=)